Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (11): 923-934.DOI: 10.5246/jcps.2023.11.074
• Original articles • Previous Articles Next Articles
Daiying Zhou, Jing Chen, Zhigang Lv*()
Received:
2023-05-18
Revised:
2023-06-13
Accepted:
2023-08-23
Online:
2023-12-02
Published:
2023-12-02
Contact:
Zhigang Lv
Supporting:
Daiying Zhou, Jing Chen, Zhigang Lv. Network pharmacology prediction and molecular docking-based study on the mechanism of Erigeron breviscapus in the treatment of age-related macular degeneratio[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 923-934.
[1] |
Armento, A.; Ueffing, M.; Clark, S.J. The complement system in age-related macular degeneration. Cell Mol. Life Sci. 2021, 78, 4487–4505.
|
[2] |
Chakravarthy, U.; Peto, T. Current perspective on age-related macular degeneration. JAMA. 2020, 324, 794.
|
[3] |
Wong, W.L.; Su, X.Y.; Li, X.; Cheung, C.M.G.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health. 2014, 2, e106–e116.
|
[4] |
Keenan, T.D.L.; Cukras, C.A.; Chew, E.Y. Age-related macular degeneration: epidemiology and clinical aspects. Adv. Exp. Med. Biol. 2021, 1256, 1–31.
|
[5] |
Campagne, M.V.; LeCouter, J.; Yaspan, B.L.; Ye, W.L. Mechanisms of age-related macular degeneration and therapeutic opportunities. J. Pathol. 2014, 232, 151–164.
|
[6] |
Mitchell, P.; Liew, G.; Gopinath, B.; Wong, T.Y. Age-related macular degeneration. Lancet. 2018, 392, 1147–1159.
|
[7] |
Wu, R.X.; Liang, Y.; Xu, M.; Fu, K.; Zhang, Y.L.; Wu, L.; Wang, Z. Advances in chemical constituents, clinical applications, pharmacology, pharmacokinetics and toxicology of erigeron breviscapus. Front Pharmacol. 2021, 12, 656335.
|
[8] |
Fan, H.; Lin, P.; Kang, Q.; Zhao, Z.L.; Wang, J.; Cheng, J.Y. Metabolism and pharmacological mechanisms of active ingredients in Erigeron breviscapus. Curr. Drug Metab. 2021, 22, 24–39.
|
[9] |
Zhu, J.Y.; Chen, L.; Qi, Y.; Feng, J.; Zhu, L.; Bai, Y.J.; Wu, H.J. Protective effects of Erigeron breviscapus Hand.–Mazz. (EBHM) extract in retinal neurodegeneration models. Mol. Vis. 2018, 24, 315–325.
|
[10] |
Ru, J.L.; Li, P.; Wang, J.N.; Zhou, W.; Li, B.H.; Huang, C.; Li, P.D.; Guo, Z.H.; Tao, W.Y.; Yang, Y.F.; Xu, X.; Li, Y.; Wang, Y.H.; Yang, L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014, 6, 13.
|
[11] |
The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017, 45, D158–D169.
|
[12] |
Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; Jensen, L.J.; Mering, C.V. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613.
|
[13] |
Zhou, Y.Y.; Zhou, B.; Pache, L.; Chang, M.; Khodabakhshi, A.H.; Tanaseichuk, O.; Benner, C.; Chanda, S.K. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019, 10, 1523.
|
[14] |
Yang, X.H.; Liu, H.H.; Liu, J.N.; Li, F.; Li, X.H.; Shi, L.L.; Chen, J.W. Rational selection of the 3D structure of biomacromolecules for molecular docking studies on the mechanism of endocrine disruptor action. Chem. Res. Toxicol. 2016, 29, 1565–1570.
|
[15] |
Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y.; Study Group, M.A.R.I.A.A. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1419–1431.
|
[16] |
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.S.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L. 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012, 119, 1388–1398.
|
[17] |
Boyer, D.S.; Schmidt-Erfurth, U.; van Lookeren Campagne, M.; Henry, E.C.; Brittain, C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017, 37, 819–835.
|
[18] |
MacLaren, R.E.; Bennett, J.; Schwartz, S.D. Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology. 2016, 123, S98–S106.
|
[19] |
Wu, D.Y.; Wang, X.D.; Cai, J.M.; Li, Y.; Bi, M.; Gui, W.W.; Cao, H.M. Study on the mechanism of Danggui Buxue Decoction in the treatment of diabetic retinopathy based on network pharmacology and experiment. J. Chin. Pharm. Sci. 2023, 32, 527.
|
[20] |
Dong, X.Y.; Qu, S.T. Erigeron breviscapus (vant.) hand-mazz.: a promising natural neuroprotective agent for Alzheimer’s disease. Front. Pharmacol. 2022, 13, 877872.
|
[21] |
Yang, L.; Tao, Y.W.; Luo, L.L.; Zhang, Y.; Wang, X.B.; Meng, X.L. Dengzhan Xixin injection derived from a traditional Chinese herb Erigeron breviscapus ameliorates cerebral ischemia/reperfusion injury in rats via modulation of mitophagy and mitochondrial apoptosis. J. Ethnopharmacol. 2022, 288, 114988.
|
[22] |
Gao, J.L.; Chen, G.; He, H.Q.; Liu, C.; Xiong, X.J.; Li, J.; Wang, J. Therapeutic effects of breviscapine in cardiovascular diseases: a review. Front. Pharmacol. 2017, 8, 289.
|
[23] |
Zhong, Y.S.; Xiang, M.H.; Ye, W.; Cheng, Y.; Jiang, Y.Q. Visual field protective effect of Erigeron breviscapus (vant.) hand. mazz. extract on glaucoma with controlled intraocular pressure. Drugs R D. 2010, 10, 75–82.
|
[24] |
Yin, S.; Wang, Z.F.; Duan, J.G.; Ji, L.; Lu, X.J. Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells. Int. J. Ophthalmol. 2015, 8, 1101–1106.
|
[25] |
Xi, J.X.; Rong, Y.Z.; Zhao, Z.F.; Huang, Y.H.; Wang, P.; Luan, H.L.; Xing, Y.; Li, S.Y.; Liao, J.; Dai, Y.; Liang, J.Y.; Wu, F.H. Scutellarin ameliorates high glucose-induced vascular endothelial cells injury by activating PINK1/Parkin-mediated mitophagy. J. Ethnopharmacol. 2021, 271, 113855.
|
[26] |
Ye, J.Z.; Zeng, B.; Zhong, M.Y.; Li, H.C.; Xu, L.H.; Shu, J.X.; Wang, Y.F.; Yang, F.; Zhong, C.S.; Ye, X.J.; He, X.H.; Ouyang, D.Y. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling. Acta Pharm. Sin. B. 2021, 11, 112–126.
|
[27] |
Kaarniranta, K.; Blasiak, J.; Liton, P.; Boulton, M.; Klionsky, D.J.; Sinha, D. Autophagy in age-related macular degeneration. Autophagy. 2023, 19, 388–400.
|
[28] |
Kauppinen, A.; Paterno, J.J.; Blasiak, J.; Salminen, A.; Kaarniranta, K. Inflammation and its role in age-related macular degeneration. Cell Mol. Life Sci. 2016, 73, 1765–1786.
|
[29] |
Celkova, L.; Doyle, S.L.; Campbell, M. NLRP3 inflammasome and pathobiology in AMD. J. Clin. Med. 2015, 4, 172–192.
|
[30] |
Ildefonso, C.J.; Biswal, M.R.; Ahmed, C.M.; Lewin, A.S. The NLRP3 inflammasome and its role in age-related macular degeneration. Retinal. Degenerat. Dis. 2016, 854, 59–65.
|
[31] |
Dowling, J.K.; O’Neill, L.A.J. Biochemical regulation of the inflammasome. Crit. Rev. Biochem. Mol. Biol. 2012, 47, 424–443.
|
[32] |
Bauernfeind, F.G.; Horvath, G.; Stutz, A.; Alnemri, E.S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.H.; Monks, B.G.; Fitzgerald, K.A.; Hornung, V.; Latz, E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183, 787–791.
|
[33] |
Tseng, W.A.; Thein, T.; Kinnunen, K.; Lashkari, K.; Gregory, M.S.; D'Amore, P.A.; Ksander, B.R. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013, 54, 110–120.
|
[34] |
Marneros, A.G. NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep. 2013, 4, 945–958.
|
[35] |
Liu, R.T.; Gao, J.Y.; Cao, S.J.; Sandhu, N.; Cui, J.Z.; Chou, C.L.; Fang, E.; Matsubara, J.A. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013, 54, 2225.
|
[36] |
Ruan, Y.; Jiang, S.B.; Musayeva, A.; Gericke, A. Oxidative stress and vascular dysfunction in the retina: therapeutic strategies. Antioxidants. 2020, 9, 761.
|
[37] |
Wang, Z.; Yu, J.G.; Wu, J.B.; Qi, F.; Wang, H.L.; Wang, Z.G.; Xu, Z.J. Scutellarin protects cardiomyocyte ischemia-reperfusion injury by reducing apoptosis and oxidative stress. Life Sci. 2016, 157, 200–207.
|
[38] |
Wang, Z.H.; Zhang, P.F.; Zhao, Y.P.; Yu, F.R.; Wang, S.Y.; Liu, K.W.; Cheng, X.; Shi, J.; He, Q.T.; Xia, Y.N.; Cheng, L. Scutellarin protects against mitochondrial reactive oxygen species-dependent NLRP3 inflammasome activation to attenuate intervertebral disc degeneration. Front. Bioeng. Biotechnol. 2022, 10, 883118.
|
[1] | Mengyao Wu, Lu Liu, Peng Zhang, Lele Zhang, Yun Gong, Xiuwei Yang. Exploring the mechanism of Buxue Yimu Pills on postpartum abdominal pain through network pharmacology and experimental validation [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 691-703. |
[2] | Ping Shang, Lin Liu, Yi Fang. Investigating the mechanism of action of Gui Zhi Fu Ling Wan in the treatment of endometriosis based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 704-719. |
[3] | Gedi Zhang, Gengxin Liu, Ziyou Yan. Therapeutic efficacy evaluation and mechanism of action based on meta-analysis and network pharmacology of Li Chong Decoction (Bolus) for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 720-735. |
[4] | Dongyan Wu, Xiaodan Wang, Jinmiao Chai, Qinqing Li, Yue Li, Mei Bi, Wanwei Gui, Huimin Cao. Study on the mechanism of Danggui Buxue decoction in the treatment of diabetic retinopathy based on network pharmacology and experiment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 527-538. |
[5] | Huan Yan, Jian Wang, Hao Fu, Min Yang, Miao Qu, Zhie Fang. Discussion on the potential target and mechanism of Dachaihu Decoction in treating hyperlipidemia based on network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 446-459. |
[6] | Mengya Wang, Kuanyou Zhang, Xin Chen, Hao Fu, Shouchun Peng. Study on the mechanism of Rhinoceros Horn and Rehmannia Decoction in the treatment of systemic lupus erythematosus based on the method of network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 351-359. |
[7] | Guangzhi Shen, Xingang Cui, Zhimin Na, Yulong Zou, Guihua Zou. A network pharmacology approach to explore the pharmacological mechanism of Epimedium brevicornum in sexual dysfunction [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 379-391. |
[8] | Min Ao, Minglan Bao, Yaxing Hou, Ying Yue, Huifang Li, Guohua Wu, Su Ri Ga La Tu. Study on the mechanism of Mongolian medicine Herba Lomatognii against acute liver injury based on network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 268-282. |
[9] | Yajing Li, Yawen Bai, Yu Du, Changhong Yan, Chunjie Ma, Lining Sun, Fengyue Bu, Haoyang Yan. Yu Ping Feng Powder for chronic glomerulonephritis treatment: A meta-analysis and network pharmacology study [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(12): 1006-1026. |
[10] | Zhiyong Sun, Shuli Gao, Yang Zhang, Gangqiang Xue, Zilin Yuan, Shaonan Wang. Study on the potential mechanism of Pu Gong Ying in treating breast hyperplasia based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 893-910. |
[11] | Yuqian Zhang, Haiying Niu, Yiran Jin. Network pharmacology-based strategy to investigate anticancer mechanisms of Catharanthus roseus (L.) G. Don [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 911-922. |
[12] | Dongsheng Wei, Xiaosheng Liu, Luzhen Li, Jiajie Qi, Yuxuan Wang, Zhe Zhang. Unraveling the biological and immunological mechanisms of safflower-danshen in the treatment of coronary atherosclerotic heart disease: a comprehensive bioinformatics and single-cell sequencing approach [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 796-812. |
[13] | Ning Ding, Tao Zhang, Ji Luo, Haochen Liu, Yu Deng, Yongheng He. Study on the mechanism of Baishao Qiwu Decoction in the treatment of colorectal cancer based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(1): 17-31. |
[14] | Ipargul Hafiz, Zhaozhi Wang, Hongji He, Zhezhe Li, Mei Wang. Exploring the mechanism of Peganum harmala L. seeds on hepatocellular carcinoma based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(7): 517-529. |
[15] | Weiping Zhao, Qi Ge, Zijun Ding, Leizhi Pan, Ziqing Gu, Yang Liu, Hua Cai. Network pharmacology and metabolomics-based detection of the potential pharmacological effects of the active components in Chrysanthemum morifolium 'Chuju' [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 412-428. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||